Indeed, IL-6 has been shown to promote invasion capability and is a marker for poor outcome in breast cancer patients [39, 42, 127–129] and increased IL-6 serum levels are associated with increased metastatic spread [130]. Here, IL6 is linked to breast carcinoma.